



GI Therapies receives marketing approval in Europe (CE Mark) for its flagship product Rhythm.IC®

Melbourne; December 21 2016. GI Therapies Pty Ltd (www.githerapies.com) today announced that it had received marketing approval in Europe (CE Mark) for its flagship product Rhythm.IC®¹.

Rhythm.IC is a non-invasive medical device designed to treat chronic constipation in adults and children. The product delivers a comfortable level of electrical stimulation to the lower abdomen to increase bowel motility. The product is used at home for an hour per day. Clinical data indicates that most patients report a benefit within 1-3 months. The benefits include increased defaecation frequency, less abdominal pain and bloating and an improvement in a number of quality of life measures.

The technology was first developed at the Murdoch Childrens Research Institute in Melbourne. Initial studies were with children with intractable constipation. Later studies have also shown to be of benefit in adults.

The Company is now looking to secure marketing approval in the US.

For further information contact:

Dr David Fisher
+61 412 06 1431
dfisher@githerapies.com

About GI Therapies

GI Therapies was established in Melbourne in 2012 to commercialise innovative technology the treat gastrointestinal motility disorders including chronic constipation and abdominal pain associated with constipation.

The technology - transabdominal gastrointestinal stimulation - TAGS® - delivers non-invasive interferential electrical stimulation to the lower abdomen. The initial product, Rhythm IC®, consists of a garment (belt) that houses an electrode array on the front and back of the abdomen and a stimulator unit. Once fitted and training provided by a health care professional, the product is used at home and is suitable for adults and children.

GI Therapies has been supported with grants by the Australian Government through Accelerating Commercialisation, an element of the Entrepreneurs Programme.

-ENDS-

¹ Rhythm.IC has not been cleared for marketing in the US at this time.